PharmacoEconomics & Outcomes News 804, p34 - 2 Jun 2018 Teledermoscopy for skin cancer referral: justifiable cost? Teledermoscopy for referral to a dermatologist in patients with suspected skin cancer in Australia appears to increase the cost of diagnosis compared with usual care but the cost may be justifiable in terms of faster clinical resolution, according to findings of a study published in JAMA Dermatology. A decision-analytic model of primary care in Australia was used to evaluate the cost effectiveness of teledermoscopy referral for skin cancer diagnosis and management by a dermatologist, compared with usual care (written referral) for patients with suspected skin cancer, from the Australian healthcare system perspective. Effectiveness was measured by time to clinical resolution (dermatologist diagnosis, or excision of the lesion by a general practitioner). The estimated time to clinical resolution was shorter with teledermoscopy referral than with usual care (9 vs 35 days; difference 26 days; 95% Credible Interval [CrI] 13, 38 days). However, the estimated cost per patient was higher with teledermoscopy referral than with usual care ($318.39 vs $263.75; difference $54.64; 95% CrI $22.69, $97.35). The estimated incremental cost- effectiveness ratio for teledermoscopy versus usual care was $2.10 per day saved to clinical resolution. "Implementation recommendations depend on the preferences of the Australian health system decision makers for either lower cost or expedited clinical resolution," concluded the authors. "Further research around the clinical significance of expedited clinical resolution and its importance for patients could inform implementation recommendations for the Australian setting," they commented. * Australian dollars Snoswell CL, et al. Cost-effectiveness of Skin Cancer Referral and Consultation Using Teledermoscopy in Australia JAMA Dermatology : 9 May 2018. Available from: URL: http://dx.doi.org/10.1001/jamadermatol.2018.0855 803321889 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera